AllDocs -> cancers

53. 9. Hartung HP, Stoll G, Toyka KV. Immune reactions in the peripheral nervous system. Peripheral Neuropathy. Philadelphia: Saunders, 1993: 418–454: 10. Jann S, Santilli IM, Scarpini E, Gatti A, Bramerio MA. Peripheral nervous system involvement after orthotopic liver transplantation [Abstract]. Neurology 1999; 52(2): A83. 11. Ropper AH. The Guillain-Barre Syndrome. The N Engl J Med 1992; 326: 1130–1136. 12. Haymaker W, Kernohan JW. The Landry-Guillain-Barre syndrome: clin- icopathologic report of fifty fatal cases and a critique of the literature. Medicine 1949; 28: 59–141. 13. Honaver M, Tharakan JKJ, Hughes RAC, Leibowitz S, Winer JB. A clinicopathological study of the Guillain-Barre syndrome: nine cases and literature review. Brain 1991; 114: 1245–1269. 14. Kaldor J, Speed BR. Gillain-Barre syndrome and Campylobacter jejuni, a serological study. Br Med J 1984; 288: 1867–1870. 15. Koski ...

In the cancer called diffuse large B-cell lymphoma , certain white blood cells—B cells—in the lymph tissues proliferate out of control. These malignant immune cells crowd out their healthy comrades and impair a person’s ability to fight disease. Standard chemotherapy sends this lymphoma into remission only in 30 to 40 percent of patients. Scientists in Europe now report that a drug called rituximab, or Rituxan, boosts the remis- sion rate significantly. The researchers treated more than 300 patients who had large B-cell lymphoma , giving about half of them intravenous rituximab plus an infusion of four standard chemotherapy drugs. The other patients received standard chemotherapy alone. Treated in hospitals and clinics in France, Belgium, or Switzerland, all were between age 60 and 80. They each received eight treatments over 6 weeks. One year after the treatments, 83 percent of the people getting rituximab were still alive, ...

NH LYMPHOMA BOTH SEXES TABLE 1A. -- Characteristics of persons reported to the Danish Cancer Registry with an initial non-Hodgkin's lymphoma , 1943-80+ _ Category Male Female Total _ No. with first primary cancer* 3,655 2,886 6,541 No. who developed a second primary cancer 105 102 207 Average age at diagnosis of first cancer, yr 57 60 58 Average yr of diagnosis of first cancer 1966 1967 1966 Person-yr of follow-up 12,462 10,443 22,905 Average follow-up, yr 3.4 3.6 3.5 Percent given radiotherapy for first cancer 63 63 63 _ + ICD-7 codes = 200, 202. * Number excludes all persons who survived less than 2 mo after the diagnosis of their first primary cancer or who developed a simultaneous cancer during this period. First primary cancers diagnosed only at autopsy or by death certificate are also excluded as are in situ cancers. TABLE 1B. -- Microscopic confirmation among persons who ...

NH LYMPHOMA BOTH SEXES TABLE 1A. -- Characteristics of persons reported to the Connecticut Tumor Registry with an initial non-Hodgkin's lymphoma , 1935-82+ _ Category Male Female Total _ No. with first primary cancer* 3,539 3,195 6,734 No. who developed a second primary cancer 196 123 319 Average age at diagnosis of first cancer, yr 56 60 58 Average yr of diagnosis of first cancer 1966 1967 1967 Person-yr of follow-up 14,378 12,854 27,231 Average follow-up, yr 4.1 4.0 4.0 Percent given radiotherapy for first cancer 52.0 50.5 51.3 _ + ICD-O morphology codes = 9590-9642,9690-9701,9750. * Number excludes all persons who survived less than 2 mo after the diagnosis of their first primary cancer or who developed a simultaneous cancer during this period. First primary cancers diagnosed only at autopsy or by death certificate are also excluded as are in situ cancers. TABLE 1B. -- Microscopic ...

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 300 A BASIC INFORMATION DESCRIPTION Malignant tumor of the lymphoid tissue (this is more common than Hodgkin’s disease). It involves the lym- phocytes (white blood cells), lymph glands (glands that fight infection and produce immune substances) and spleen (a large lymph gland). It can affect all ages, but is most common in men in their 40’s. FREQUENT SIGNS AND SYMPTOMS • Swollen, non-tender, rubbery, distinct lymph glands anywhere in the body but most commonly in the armpit, neck or groin. • Weight loss. • General ill feeling. • Anemia. • Bleeding from the gastrointestinal tract. • Jaundice (yellow skin and eyes). CAUSES Unknown, but research suggests a virus infection may be a factor or suppression of the immune system, par- ticularly after organ transplantation. One type ...

Cisco Systems, Inc. All contents are Copyright © 1992–2004 Cisco Systems, Inc. All rights reserved. Important Notices and Privacy Statement. Page 1 of 3 EXECUTIVE SUMMARY CUSTOMER NAME The Leukemia & Lymphoma Society INDUSTRY Healthcare BUSINESS CHALLENGE Raise additional funds Enhance patient and family support services Improve business communications and maintain monthly network operating costs NETWORK SOLUTION High-performance Cisco switches and routers Cisco VPN concentrators BUSINESS VALUE Enhanced communication facilitates patient and family support services and fund-raising event coordination Network infrastructure supports new technologies for enhancing business operations and reducing operating expenses ABSTRACT A Cisco foundation ...

GUIDELINES Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas S.J.WHITTAKER, J.R.MARSDEN,* M.SPITTLE AND R.RUSSELL JONES St John’s Institute of Dermatology, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, U.K. * Department of Dermatology, Selly Oak Hospital, Birmingham B29 6JD, U.K. Department of Dermatology, Ealing Hospital, Uxbridge Road, Southall UB1 3HW, U.K. Department of Oncology, Middlesex Hospital, Mortimer St, WIN 8AA, U.K. Accepted for publication 9 July 2003 These guidelines were commissioned by the British Association of Dermatologists guidelines and therapeutics subcommittee. Members of the committee are N.H.Cox (Chairman), A.S.Highet, D.Mehta, R.H.Meyrick Thomas, A.D.Ormerod, J.K.Schofield, C.H.Smith and J.C.Sterling. Members of the ...

Non-Hodgkin Lymphoma Protocol applies to non-Hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures • Cytology (No Accompanying Checklist) • Biopsy • Resection of Lymph Node or Other Organ Authors Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada Jonathan Said, MD Department of Pathology, UCLA School of Medicine, Los Angeles, California For the Members of the Cancer Committee, College of American Pathologists Previous contributors: Nancy L. Harris, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Judith Ferry, MD; Claire Fung, MD; Irene Kuter, MD; Peter Mauch, MD Page 2 Non-Hodgkin Lymphoma • Hematologic System CAP Approved 2 © 2005. College ...

Gastrointestinal Lymphoma Protocol applies to Hodgkin and non-Hodgkin lymphomas of the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC TNM staging system Procedures • Cytology (No Accompanying Checklist) • Incisional Biopsy (No Accompanying Checklist) • Resection Author Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada For the Members of the Cancer Committee, College of American Pathologists Previous contributor: Leslie H. Sobin, MD Page 2 Gastrointestinal Lymphoma • Hematologic System CAP Approved 2 © 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols ...

lymphoma T cell Leukemia/ Lymphoma T cell Lymphoblastic Lymphoma /Leukemia Post Thymic Leukemias/Lymphomas Prolvmphocytic leukemia/ T cell CLL Adult T cell leukemia/ lymphoma Cutaneous T-cell leukemia/ lymphoma Sezary Syndrome Mycosis Fungoides Peripheral T cell lymphoma Large granular lymphocytic (LGL) T cell Lymphoblastic Lymphoma /Leukemia Characteristics Patients tend to be young adults/adolescents 50-80% present with mediastinal mass (pre B -rarely) Peripheral blood involvement >30% at presentation Rapidly progressive w/ dissemination to BM & CSF. Poor prognosis Flow cytometry - excellent - since immature T cell phenotype (while a normal cellular phenotype) is not expected in the sample most commonly submitted (LN, PBL, CSF, pleural ...

Non-Hodgkins Lymphoma – C82-C85 Cancer Statistics Cancer affects all ages, however, is predominately a disease that affects the elderly; the rate of cancer in any age-group rises continuously in both males and females from about the age of 30. The statistics presented here fall into three groups: Incidence, Mortality and Survival. Incidence and Mortality are reported in three ways : 1) Number: this is simply the number of cases cancer in an area and will depend on the population of that area and on the age structure of its population as well as on the underlying rate of cancer. 2) Crude rate per 100,000 population: this is the number of cases of cancer in an area divided by the population of that area. This measure takes account of the size of that population, but not its age structure; it would tend to be higher in areas where the population is older. 3) Age standardised rate per 100,000 ...

2007 Pan Pacific Lymphoma Conference PROGRAM FACULTY Lynne V. Abruzzo, MD, PhD Associate Professor Department of Hematopathology The University of Texas M. D. Anderson Cancer Center Houston, Texas Patricia Aoun, MD, MPH Associate Professor Department of Pathology and Microbiology University of Nebraska Medical Center Omaha, Nebraska James O. Armitage, MD Professor Section of Hematology/Oncology Department of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska Tracy T. Batchelor, MD Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology Massachusetts General Hospital Harvard Medical School Boston, Massachusetts Phillip J. Bierman, MD Associate Professor Section of Hematology/Oncology Department of Internal Medicine University of Nebraska Medical ...